WHAT’S NEW IN CARDIOVASCULAR PREVENTION?

REFERENCES

• Yusuf S, Hawken S, Bunpunu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lan-cet 2004; 149: 54–60.
   Google Scholar
• Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. European Heart] 2007; 28: 2375–414.
   PubMed Web of Science ®Google Scholar
• De Backer G, De Bacquer D, Brohet C, et al. Recommandations relatives a la prevention des maladies cardiovasculaires en pratique clinique. Louvain Medical 2005; 4: 158–69.
   Google Scholar
• Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocar-dial infarction. Time-cou rse analyses of the results of the GISSI-Prevenzione. Circulation 2002; 105: 1897–903.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Hawken S, bunpunu S, et al. Obesity and the risk of myocardial infarction in 27000 participants from 52 countries: a case-control study. Lancet 2005; 366: 1640–49.
   PubMed Web of Science ®Google Scholar
• Brohet C. Le tour de taille : un nouveau marqueur du risque ca rd iovascu la ire en Belgique. L'étude « BEST ». Louvain Medical 2006; 3: 590–96.
   Google Scholar
• Pitt B, Waters B, Brown WV, et al. Agressive lipid - lowering therapy compared with angioplasty in stable coronary artery disease. N EngIJ Med 1999; 341: 70–6.
   PubMed Web of Science ®Google Scholar
• Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356: 1503–16.
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, et al. European Society of hypertension (ESH) and European Society of Cardiology (ESC) guidelines for the management of arterial hypertension. J Hy-pertens 2007; 25: 1105–87.
   Google Scholar
• Klingbeil J, Schneider M, Martus P, Messerli FH, Schmieder RE. A metaanalysis of the effects of treatment on left ventricular mass in essential hypertension. Am] Med 2003; 115:41–46.
   PubMed Web of Science ®Google Scholar
• Dahl& B, Sever P, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required vs.Atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian cardiac outcomes Trial - Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366:895–906.
   Google Scholar
• Baigent C, Keich A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment : prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267–78.
   PubMed Web of Science ®Google Scholar
• Bjelakovic G, Nikolova D, Lotte Gluud L, Simonetti RG, Gluud Chr. Mortality in randomized trials of antioxydant supplements for primary and secondary prevention. Systematic review and meta-a na lysis.JAMA 2007; 297: 842–57.
   Google Scholar
• Toole JF, Malinow MR, Chambless LF, et al. Lowering homo-cysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction and death: the vitamin intervention for stroke prevention (VISP) randomised controlled /AMA 2004; 291: 565–75.
   PubMed Web of Science ®Google Scholar
• Bonaa KH, Njolstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Eng(' Med 2006; 354: 1578–88.
   PubMed Web of Science ®Google Scholar
• The heart Outcomes Prevention Evaluation (HOPE) 2 Investiga-tors. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Eng(' Med 2006; 354: 1567–77.
   Web of Science ®Google Scholar
• Loscalzo J. Homocysteine trials - clear outcomes for complex reasons. N EngIJ Med 2006; 354: 1629–32.
   PubMed Web of Science ®Google Scholar
• Nissen S, Tardif JCL Nicholls Si, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Eng(' Med 2007; 35: 1304–16.
   Google Scholar
• Rozanski A, Blumenthal JA, Davidson KW, Saab PG, Kubzanski L. The epidemiology, pathophysiology and management of psy-chosocial risk factors in cardiac pratice: the emerging field of behavioural ca rdiologyj Am Coll Cardiol 2005; 45:637–56.
   Google Scholar